• Article highlight
  • Article tables
  • Article images

Article History

Received : 16-01-2023

Accepted : 13-02-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 440

PDF Downloaded: 292


Get Permission Goyal and Jaimini: Stability indicating RP-HPLC method development and validation for simultaneous estimation of cilnidipine and bisprolol fumarate in synthetic mixture


Introduction

Cilnidipine protects the end organs from the potentially damaging consequences that hypertension might have. The elderly, diabetics, and albuminurics are three groups of persons who can benefit from consuming it. Cilnidipine is being used by an increasing number of patients who are afflicted with chronic renal disease. High blood pressure is also referred to as hypertension in some circles. The force that is generated when the blood that is pumped by the heart presses against the walls of the blood vessels is referred to as blood pressure. A disorder that can cause irreversible damage to the blood vessels is high blood pressure, which is also known as hypertension. Bisoprolol is prescribed to patients with hypertension that is either mild or severe in severity. Treatment of illnesses such as heart failure, atrial fibrillation, and angina pectoris are examples of off-label usage of a drug.1 The combination of these two drugs Cilnidipine and Bisoprolol is used in the treatment of Hypertension (high blood pressure). Cilnidipine and bisoprolol lower blood pressure effectively. Several analytical methods are available which can determine individually or in combination with another drug. From detailed review of literature, it was found that no analytical method is available for determination of this combination and its degradants from simulated mixture or formulation. So, for the same reason stability indicating RP — HPLC method was selected.2, 3, 4, 5, 6, 7

Materials and Methods

CIL (99.98% pure) and BIS (99.96% pure) were obtained as gift sample for research purpose from, Cadila Healthcare Ltd., Sanand. Acetonitrile (HPLC grade), Orthophosphoric acid (LR grade) was purchase from S. D. fines.

Preparation of stock solution

  1. BIS: Accurately weighed 5 milligram drug dissolved in 100 millilitre methyl alcohol (50 μg/millilitre). 1.0 millilitre from Stock Solution and make up to 10millilitre with mobile phase (5 μg/millilitre).

  2. CIL: Accurately weighed 10 milligram drug dissolved in 100 millilitre methyl alcohol (100 μg/millilitre). 1.0 millilitre from Stock Solution and make up to 10millilitre with mobile phase (10 μg/millilitre).8

Selection of analytical wavelength

Working standards of BIS (10 µg/millilitre) and CIL (10 µg/millilitre) were scanned in UV 200 – 400 nanometer region and overlapped.9, 10, 11, 12, 13, 14, 15

Table 1

Preparation of solution for accuracy studies

Concentration of stock solution

25 µg/millilitre of CIL and 12.5 µg/millilitre of BIS

Volume taken from SS

-

2.0 millilitre

4.0 millilitre

8.0 millilitre

Amount of Placebo added

200 milligram

200 milligram

200 milligram

200 milligram

Volume made up with

10 millilitre

10 millilitre

10 millilitre

10 millilitre

Diluent

Mobile phase

Mobile phase

Mobile phase

Mobile phase

Final Concentration

-

5+2.5 µg/millilitre

10+5 µg/millilitre

20+10 µg/millilitre

Identification

Unspiked

50 % Spiked

100 % Spiked

150 % Spiked

Table 2

System suitability parameter of CIL and BIS

Parameter

CIL (n=3)

BIS (n=3)

Mean

± SD

RSD

Mean

± SD

RSD

Retention time (Rt)

3.04

0.01

1.52

15.12

0.01

0.31

Tailing Factor

1.31

0.02

1.36

1.19

0.02

0.67

Number of theoretical plates

12417

22.48

1.20

7583

32.42

1.69

Resolution (Rs)

Mean (9.84) SD (0.07) RSD (1.32)

Table 3

Evaluation table of forced degradation studies

Stress Condition

Area

CIL

BIS

% Degradation (CIL)

% Degradation (BIS)

Acid Hydrolysis

Standard Area

488875

304876

13.77 %

10.41 %

Observed Area

421543

273122

Base Hydrolysis

Standard Area

488875

304876

14.00 %

12.87 %

Observed Area

420431

265613

Oxidative Stress

Standard Area

488875

304876

13.46 %

12.59 %

Observed Area

423045

266478

Thermal Degradation

Standard Area

488875

304876

12.59 %

10.97 %

Observed Area

427324

271428

Table 4

Linearity data of CIL

Sr. No.

Conc. (µg/millilitre)

Mean

± SD (n=3)

RSD

1

5

206751.4

7778.06

1.76

2

10

421172.6

6989.08

1.66

3

15

637635.2

3544.88

0.56

4

20

822667.2

7669.76

0.93

5

25

992189

4990.28

0.51

Table 5

Linearity data of BIS

Sr. No.

Conc. (µg/millilitre)

Mean

± SD (n=3)

RSD

1

2.5

196331.2

3558.13

1.81

2

5

307226.8

3120.45

1.02

3

7.5

438759.4

6720.61

1.53

4

10

561795.6

6669.63

1.19

5

12.5

660774.4

6020.37

0.91

Table 6

Repeatability data of CIL

Sr.No.

Concentration (µg/millilitre) (n=5)

5

10

15

20

25

1.

200248

428875

638666

822385

991345

2.

202345

417265

641256

834245

994212

3.

218688

422554

636386

820238

984177

4.

201921

425847

639725

823524

997512

5.

210555

411322

632143

812944

993699

Mean

206751.4

421172.6

637635.2

822667.2

992189

± SD

7778.06

6989.08

3544.88

7669.76

4990.28

RSD

1.76

1.66

0.56

0.93

0.50

Table 7

Repeatability data of BIS

Sr. No.

Concentration (µg/millilitre) (n=5)

2.5

5

7.5

10

12.5

1.

193633

304876

443844

561128

667288

2.

198289

304495

429834

567487

653798

3.

199899

306556

433731

569445

656845

4.

191541

312220

440899

553687

659176

5.

198294

307987

445489

557231

666765

Mean

196331.2

307226.8

438759.4

561795.6

660774.4

± SD

3558.13

3120.45

6720.61

6669.63

6020.37

RSD

1.81

1.02

1.53

1.19

0.91

Table 8

Intraday andinterday precision data of CIL

Concentration (µg/millilitre)

Intraday Mean

+ SD (n=3)

RSD

Inter-Day Mean

+ SD (n=3)

RSD

7.5

327058

3953.83

1.21

327186

4155.15

1.27

12.5

653869.66

6620.16

1.01

653918

6467.48

0.99

17.5

966840.33

10883.98

1.13

966737.66

10841.14

1.12

Table 9

Intraday andinterday precision data of BIS

Concentration (µg/millilitre)

Intraday Mean

+ SD (n=3)

RSD

Inter-Day Mean

+ SD (n=3)

RSD

2.5

196607.66

4369.61

1.22

197181.33

2999.54

1.52

7.5

434512.66

5527.43

1.27

434449.66

5498.80

1.27

12.5

661064.33

5393.07

0.82

660840

5089.32

0.77

Table 10

Accuracy data of CIL by HPLC method

Level of spiking

Amount of placebo (milligram)

Amount of drug added (µg/millilitre)

Amount of drug recovered (µg/millilitre)

% Recovery

% Mean Recovery ± SD (n=3)

50%

200

5

5.02

100.40

100.67 ± 1.03

5

5.09

101.80

5

4.99

99.80

100%

200

10

10.14

101.40

100.57 ± 1.19

10

9.92

99.20

10

10.11

101.10

150%

200

20

20.22

101.10

101.15 ± 0.58

20

20.35

101.75

20

20.12

100.60

Table 11

Accuracy data of BIS by HPLC method

Level of spiking

Amount of placebo (milligram)

Amount of drug added (µg/millilitre)

Amount of drug recovered (µg/millilitre)

% Recovery

% Mean Recovery ± SD (n=3)

50%

200

2.5

2.52

100.80

100.27 ± 0.61

2.5

2.49

99.60

2.5

2.51

100.40

100%

200

5

5.11

102.20

101.27 ± 1.29

5

5.09

101.80

5

4.99

99.80

150%

200

10

10.23

102.30

100.87 ± 1.56

10

10.11

101.10

10

9.92

99.20

Table 12

Assay of CIL and BIS by HPLC method

Drug

Amount taken (µg/millilitre)

Amount found (µg/millilitre) (Mean ± SD n=5)

% Assay (Mean ± SD n=5)

CIL

10

10.14 ± 0.05

101.4 ± 0.46

BIS

5

5.06 ± 0.04

101.2 ± 0.72

Figure 1

Overlain UV Spectra of BIS (10 µg/mL) and CIL (50 µg/mL)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage1.png
Figure 2

Chromatogram of mixture of CIL and BIS using optimized chromatographic

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage2.png
Figure 3

Chromatogram of treated sample (Acid hydrolysis)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage3.png
Figure 4

Chromatogram of treated sample (Base hydrolysis)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage4.png
Figure 5

Chromatogram of treated sample (Oxidative stress)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage5.png
Figure 6

Chromatogram of treated sample (Thermal stress)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage6.png
Figure 7

Regression analysis of CIL (25 – 125 µg/mL)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage7.png
Figure 8

Regression analysis of BIS (8 – 40 µg/mL)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/457503d7-a11d-49ac-862a-1fd88e85de9aimage8.png

Preparation of Solutions for Forced Degradation Studies

Acid induced hydrolysis

Accurately weighed amount corresponding to 10 mg of CIL and 5 mg of BIS were transferred to 10 ml volumetric flask and add 5 mL of 1 N HCl. Same solution was heated under reflux condition at 60°C for 1 hour on a hot plate. After the heating cool down the solution and were neutralized with 2 N NaOH and volume was raised to mark with diluent if necessary. 0.1 mL of previous solution was further diluted to 10 mL with diluent. The resulting solution have concentration of 10 µg/mL of CIL and 5 µg/mL of BIS (Treated sample). In similar way 0-hour sample (Only difference was heating condition was not provided) and blank (Only difference is there is no addition of API) were prepared. % Degradation of both components was calculated by comparing area of treated sample and control.16

Base induced hydrolysis

Same amount of API like in former case were transferred to 10 mL volumetric flask and volume of same was raised to the mark with 5 mL 1 N NaOH. Same solution was heated under reflux condition at 60°C for 1 hour on a hot plate. After the heating cool down the solution and were neutralized with 2 N HCl and volume was raised to mark with diluent if necessary. 0.1 ml of previous solution was further diluted to 10 mL with diluent. The resulting solution have concentration of 10 µg/mL of CIL and 5 µg/mL of BIS (Treated sample). In similar way 0-hour sample and blank sample were prepared. % Degradation of both components was calculated by comparing area of treated sample and control.16

Hydrogen peroxide induced stress (Oxidative)

Same amount of API like in former case were transferred to 10 mL volumetric flask and volume of same was raised to the mark with 5 mL 3% hydrogen peroxide. Same solution was heated under reflux condition at 60°C for 1 hour on a hot plate. After the heating cool down the solution and volume was raised to mark with diluent. 0.1 ml of previous solution was further diluted to 10 mL with diluent. The resulting solution have concentration of 10 µg/mL of CIL and 5 µg/mL of BIS (Treated sample). In similar way 0-hour sample and blank sample were prepared. % Degradation of both components was calculated by comparing area of treated sample and control.16

Thermal stress

Exact quantity of CIL and BIS like in previous cases were transferred to petri dish and exposed to 70 C° for 3 hours in hot air oven and residues were reconstituted with help of acetonitrile and transferred into 10 mL volumetric flask and volume of flask was raised with the mark with same solvent. 0.1 mL of resulting solution was further diluted to 10 ml with diluent. Above solution was chromatographed and % degradation was computed by comparing against standard concentration of CIL and BIS.16

Preparation of Solutions for Analytical Method Validation

Linearity and range

Preparation of CIL (25 to 400 µg/millilitre) and BIS (4 to 64 µg/millilitre). Master Stock Solution: 5 milligram CIL and 2.5 milligram BIS dissolved in 10 millilitre MeOH. Concentration of master stock solution (µg/millilitre) CIL+BIS (500+250) µg/millilitre. Volume of master stock solution (millilitre) 0.1 – 0.5. Final dilution in 10 millilitre volumetric flask. Volume make up was done with mobile phase. Concentration of final mixture (in µg/millilitre) 5+2.5 - 25+12.5. All above solutions were injected at volume of 20 µL into column by employing optimized chromatographic conditions.17, 18, 19, 20

Intermediate precision (Repeatability)

Prepared standard mixtures having concentration of CIL (5 µg/millilitre to 25 µg/millilitre) and BIS (2.5 µg/millilitre to 12.5 µg/millilitre) were injected at volume of 20 µL into column by employing optimized chromatographic conditions. Each standard mixture was injected 5 time and peak area was monitored. Each concentration was monitored for repeatability by RSD.17, 18, 19, 20

Accuracy

Accuracy of the analytical method has been performed by spiking of placebo with the standard. Placebo for the study was selected on the basis of reported formulation. And spiking of the placebo was performed at 50, 100 and 150 % of the target concentration. (Table 1)17, 18, 19, 20

Assay

Sample Preparation: Composition of Synthetic Mixture: Composition of Placebo: HPMC (4 milligram), MCC (190 milligram), Magnesium stearate (4 milligram), Talc (2 milligram). Role of HPLC-Film forming agent, MCC- Directly compressible material, MS, gliding agent, Talk, lubricating agent CIL (10 milligram) and BIS (5 milligram) was taken into the volumetric flask (100 millilitre) and volume of the flask was raised to 100 milliliters with acetonitrile to give stock solution containing 100 µg/millilitre of CIL and 50 µg/millilitre of BIS. (Sonicate the solution for 10 minutes and filter the same from 0.45 Micro-meter Whatman filter paper.).

Test Solution: Withdraw 1.0 millilitre from above filtrate in 10 millilitre volumetric flask; make up the volume with mobile phase, which contain CIL+BIS = 10+5 µg/millilitre.17, 18, 19, 20

Result and Discussion

Selection of analytical wavelength

Working standard of Metoprolol and Bisoprolol fumarate were scanned in UV range of 200 – 400 nm and overlapped Two iso-absorptive points were observed that is 240 nm and 254 nm (Figure 1). Therefore, 245 nm was selected as analytical wavelength for further trials. As well as both the compounds gives good intensity peak at 245 nm.

Optimized chromatographic condition

When method was operated using optimized chromatographic condition a well resolved peak of CIL and BIS was observed at 3.281 and 15.114 minutes respectively (Figure 2). All the system suitability parameters were within the guidelines.

Forced degradation studies

Optimized method was found to be stability indicating as it is able to separate all the degradation products in the presence of active ingredient. (Figure 3, Figure 4, Figure 5, Figure 6) No degradation product found to interfere with estimation of CIL and BIS in stressed samples. Even the stress given found to be optimum as % degradation observed was predictive in nature (below 15%). (Table 3)

Analytical Method Validation

Linearity and range

As per ICH guidelines, the value of r2 should be greater than 0.995 and observed r2 for given concentration range for CIL and BIS is 0.998 and 0.9993 respectively. Hence, we can say that developed method is linear over the range of 5 – 25 µg/mL and 2.5 – 12.5 µg/mL for CIL and BIS respectively show in Figure 7, Figure 8. Linearity data for both drugs is shown in Table 4, Table 5.

Repeatability

When all mixtures were analyzed at all concentration, calculated relative standard deviation at each level was found to be less than 2 so that method was found to be repeatable over the range of 5 – 25 µg/mL and 2.5 – 12.5 µg/mL for CIL and BIS respectively. Repeatability data are shown in Table 6, Table 7 for CIL and BIS respectively.

Method precision

For determining inter day and intraday precision, % RSD was monitored at selected concentration level which was found to be less than 2 so method was found to be precise for estimation of CIL and BIS. Data for intermediate precision are given in Table 8 and 9 for CIL and BIS respectively.

Accuracy study

Accuracy of the analytical method has been performed by spiking of placebo with the standard. Placebo for the study was selected on the basis of reported formulation. And spiking of the placebo was performed at 50, 100 and 150 % of the target concentration. (Table 10, Table 11).

Assay

When prepared synthetic mixture was analyzed by developed and validated method, % assay was found to be 101.4 for CIL and for 101.2 BIS (Table 12).

Acknowledgment

The authors are thankful to RMS Scientific services, Anand Gujarat, India for scientific consultation.

Author Contribution

  1. Pramod Kumar Goyal, Research Scholar. Maharishi Arvind University, Jaipur.

  2. Dr Manish Jaimini, Professor & Principal, Dept of Pharmacy, Maharishi Arvind University, Jaipur.

  3. Dr Piush Sharma, Professor & Principal, Maharishi Arvind College of Pharmacy, Jaipur.

  4. Mohit Agarwal, Assistant Professor, NIMS Institute of Pharmacy, NIMS University, Jaipur.

Source of Funding

None.

Conflict of Interest

None.

References

1 

VBG Tiruveedhi VR Battula KB Bonige Novel determination of anti-hypertensive combination; benidipine hydrochloride and nebivolol hydrochloride by high performance chromatographic methodRes J Pharm Technol2021141054338

2 

Cilnidipine: Uses, Interactions, Mechanism of Action | DrugBank Online2022https://go.drugbank.com/drugs/DB09232

3 

Commission. Indian Pharmacopoeia201816167

4 

5 

CN111072552B - Preparation method of cilnidipine - Google Patents2022https://patents.google.com/patent/CN111072552B/en?q=Cilnidipine+HPLC&oq=Cilnidipine+HPLC

6 

CN102266330A - Cilnidipine preparation and preparation method thereof - Google Patents2022https://patents.google.com/patent/CN102266330A/en?q=Cilnidipine&oq=Cilnidipine+

7 

A Patel A Panchal V Patel A Nagar FTIR spectroscopic method for quantitative analysis of Cilnidipine in tablet dosage formInt J Pharma Sci Res20156710339

8 

H Paithankar HPLC Method Validation for Pharmaceuticals: A ReviewInt J Universal Pharm Bio Sci20132422940

9 

H Patel DP Damahe SB Narkhede RP-HPLC Method Development and Validation for Simultaneous Estimation of Cilnidipine and Bisoprolol Fumarate in Tablet Dosage FormInt J Chemtech Res2019120126976

10 

N Sunitha SC Mariha A Venu B Rao BA Rao Method Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Olmesartan and Cilnidipine in Bulk and FormulationsInt J Pharm Res Allied Sci20154312735

11 

RH Rupareliya HS Joshi Stability Indicating Simultaneous Validation of Telmisartan and Cilnidipine with Forced Degradation Behavior Study by RP-HPLC in Tablet Dosage FormInt Sch Res Notices20132013 46146110.1155/2013/461461

12 

JS Mital B Patel A Paramar Development and validation of RP-HPLC method for simultaneous estimation of Cilnidipine and Olmesartan medoxomil in their combined tablet dosage formInt J Pharm Biosci20144115760

13 

L Logoyda S Kovalenko AM Abdel-Megied I Zhulkevych I Drapak I Demchuk HPLC method development for the analysis of bisoprolol in combined dosage form containing bisoprolol and enalapril and in vitro dissolution studiedInt J Applied Pharma201911318694

14 

EH Rudwan A Mohammed A Saeed UV derivative spectrophotometric method for determination of bisoprolol fumarate in bulk and tablet formulationInt Res J Pune Appl Chem201714117

15 

Y Kondratova L Logoyda Y Voloshko AA Megied D Korobko Y Soroka Development and validation of HPLC-dad method for the determination of bisoprolol in tablet dosage formsInt J Applied Pharma201796549

16 

M Blessy RD Patel PN Prajapati YK Agrawal Development of forced degradation and stability indicating studies of drugs-A reviewJ Pharm Anal20144315965

17 

G Geetha V Kumar G Raja Analytical Method Validation: an Updated ReviewInt J Adv Pharm Biol Chem2012116471

18 

R Swati P Mansi P Aditya Analytical Method Development and Validation: A Concise Review (Review Article)Int J Pharm Biol Sci2021111916

19 

B Mittu AC Chauhan Analytical Method Development and Validation: A Concise ReviewJ Anal Bioanal Tech20156115

20 

M Mathur VK Devi Design of experiment utilization to develop and validate high performance liquid chromatography technique for estimation of pure drug and marketed formulations of atorvastatin in spiked rat plasma samplesInt J Pharm Sci Res20178417086



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.